OTCMKTS:OSIR Osiris Therapeutics (OSIR) Stock Price, News & Analysis $18.99 0.00 (0.00%) As of 04/17/2019 Add Compare Share Share Stock Analysis Stock Analysis About Osiris Therapeutics Stock (OTCMKTS:OSIR) Get Osiris Therapeutics alerts:Sign Up Key Stats Today's Range$18.99▼$18.9950-Day Range$18.99▼$18.9952-Week Range$7.01▼$19.30VolumeN/AAverage Volume205,753 shsMarket Capitalization$655.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Osiris Therapeutics, Inc. was a biotechnology company focused on regenerative medicine and biologic products for wound care and orthopedic applications. Its products were developed from donated human placental and other tissue sources and were designed to support the repair or regeneration of damaged tissue. The company’s best-known products included Grafix, a cryopreserved placental membrane used in wound management, and Stravix, a placental tissue product intended for surgical and wound-care applications. Osiris also developed orthopedic products, including Cartiform, a cartilage restoration product, and BIO4, a viable bone allograft used in orthopedic and reconstructive procedures. Founded in 1992 and based in Columbia, Maryland, Osiris primarily served the U.S. health-care market through hospitals, physicians and specialty distributors. Smith & Nephew completed its acquisition of Osiris in 2019, bringing the company’s regenerative-medicine business and product portfolio into Smith & Nephew’s advanced wound management and orthopedic businesses. Osiris is therefore best understood as a former independent biotechnology company rather than an operating business with a current standalone management structure.AI Generated. May Contain Errors. Read More Receive OSIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Osiris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OSIR Stock News HeadlinesOsiris Chairman responds to columnDecember 24, 2025 | marketwatch.comRyoncil, the first FDA-approved mesenchymal stromal cell therapyMarch 3, 2025 | finance.yahoo.comThis 38 Dollar Fund Holds Every Major AI Stock and Pays WeeklyThe biggest AI stocks like Nvidia, CrowdStrike, and Palantir now trade for hundreds of dollars a share. One fund owns them all for just $38 a share. This fund distributes income every Thursday, with a 34 percent annualized distribution rate, even though none of the underlying AI stocks pay dividends on their own. Tim Plaehn breaks down exactly how the fund works in a free video presentation. | Investors Alley (Ad)Global Topical Wound Agents Market Size To Exceed USD 3.7 Billion By 2033 | CAGR Of 6.89%May 25, 2024 | finance.yahoo.comKanak KantiMarch 19, 2024 | fool.comTissue Engineering Market Set to Soar Past USD 32.45 Billion by 2030February 2, 2024 | finance.yahoo.comAnti-biofilm Wound Dressing Market Size & Share to Surpass US$ 2.3 Billion by 2030 - Exclusive Report by Persistence Market ResearchJanuary 19, 2024 | finance.yahoo.comNASA launches mission to intercept ‘God of Chaos’ asteroid as it nears Earth’s orbitDecember 28, 2023 | nypost.comNSee More Headlines OSIR Stock Analysis - Frequently Asked Questions How have OSIR shares performed this year? Osiris Therapeutics' stock was trading at $18.99 at the beginning of the year. Since then, OSIR stock has increased by 0.0% and is now trading at $18.99. How do I buy shares of Osiris Therapeutics? Shares of OSIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Osiris Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Osiris Therapeutics investors own include MiMedx Group (MDXG), Bristol Myers Squibb (BMY), Ionis Pharmaceuticals (IONS) and Mesoblast (MESO). Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:OSIR Previous SymbolNASDAQ:OSIR CIK1360886 Webwww.osiris.com Phone443-545-1800FaxN/AEmployees342Year Founded1992Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares34,528,000Free FloatN/AMarket Cap$655.69 million OptionableNot Optionable BetaN/A Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:OSIR) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredPrint this before your next tradeBill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...Profits Run | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredThis little-known gold fund distributes cash every FridayGold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Osiris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Osiris Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
